|
Hemodyne technology creates today’s true state of the
art in the assessment of platelet health
Hemostasis Analysis
System
The only system in the world that delivers the
“Whole Story” from whole blood
Developed and refined over seven years, Hemodyne’s
remarkable Hemostasis Analysis System sets a new standard in platelet
and clotting assessment—an advanced level of diagnosis and control made
possible by the system’s unique ability to supply the “Whole Story.”
|
|
With
a small sample of whole blood, the Hemostasis Analysis System
provides information on key platelet and clotting properties in a
whole blood system.
|
The Hemostasis Analysis System offers the most
comprehensive
assessment of increased and decreased platelet activity, as well
as clot quality.
The “Whole Story” of
hemostatic balance
In minutes, physicians and researchers using the
Platelet Assessment
System can measure:
- Platelet activity, determined by the
Platelet Contractile Force (PCFTM) exerted by
activated platelets on the fibrin network. PCFTM is a direct measurement of platelet function.
- Clot structure, determined by clot
elastic modulus (CEM), a measure of the physical structure of the
clot’s polymerizing fibrin and its cellular components. CEM is a
measurement of clot rigidity.
- Thrombin Generation Time (TGTTM), a measurement of the time between calcium addition and
initial development of Platelet Contractile Force in clotting. The
role of thrombin in converting fibrinogen to fibrin and modulating
platelet adhesion makes TGTTM a key
parameter in clot formation and wound healing.
From Hemodyne
technology, the new standard in analysis
In its unique capability to provide the “Whole Story”
of platelet and clotting activities quickly and easily using whole
blood, Hemodyne’s Hemostasis Analysis System also overcomes the
limitations of conventional assessment systems.
Existing platelet function technology measures
platelet aggregation and adhesion, but these are only by-products— not
a true measure—of platelet activation. Thromboelastography is only a
relative measure of clot flexibility. ACT, PTT, and PT tests do not
measure platelet function or clot structure. Only the Hemostasis
Analysis System provides a true global picture from direct measurement
of key parameters.
 With
this “Whole Story” of hemostatic balance, the Hemostasis Analysis
System offers a simple alternative both for identifying patients at
risk for thrombosis (high PCFTM,
high CEM, short TGTTM)
or hemorrhage (low PCFTM,
low CEM, prolonged TGTTM)—and
for monitoring those same patients’ responses to a wide variety of
hemostatic and antithrombotic agents.
An important—and
practical—advance in assessment
From the physician’s office to the operating room to
the emergency room, the Hemostasis Analysis System’s ability to provide
a global assessment translates into new precision in:
- Improving the effectiveness
of drug dosing and monitoring,
particularly for cardiovascular and bleeding-disorder medications
that cannot be dosed or monitored by traditional methods
- Pre-surgically gauging the
risk of excessive bleeding,
to improve
surgical decision-making
- Evaluating patient
thrombotic risk, with a
system that studies show offers an inexpensive, non-invasive
method of gauging this risk
- Gauging platelet viability with the only direct indicator of
platelet force. Studies conducted by the U.S. Army and others show
that the HAS enables the direct assessment of platelet viability
without the inaccuracies inherent in typical
aggregation/thrombo-elastography-based studies. After all, even
dead platelets aggregate.
When
complete and accurate assessment is critical, the Hemostasis Analysis
System’s state-of-the-art performance is the answer, and we welcome the
opportunity to give you the “Whole Story.”
|
